AVITA Medical Highlights Largest AG真人官方-World Analysis Demonstrating Reduced Hospital Stay with RECELL
- Hospital stays reduced by 35.7% (6.2 days) compared to traditional treatments
- Significant cost savings of $300 million over 5 years
- Wide adoption with presence in over 130 U.S. burn centers
- Multiple clinical benefits including less donor skin needed, reduced pain, and faster healing
- None.
Insights
RECELL's proven 35.7% reduction in hospital stays validates its clinical and economic value proposition in burn treatment.
The latest real-world data analysis for AVITA Medical's RECELL technology presents compelling evidence of its clinical and economic benefits. The retrospective study of over 6,300 patients from 2019-2024 demonstrates a significant
The data presented at the British Burn Association Annual Meeting represents the largest real-world analysis of RECELL to date, providing robust validation of the technology's value proposition. RECELL's Spray-On Skin鈩� Cells require significantly less donor skin than traditional grafting methods, resulting in less pain, faster healing, improved outcomes, and fewer procedures.
With adoption in 130+ burn centers across the United States, RECELL has established significant market penetration. This widespread adoption, combined with demonstrable cost savings, strengthens AVITA Medical's position in the acute wound care market. The reduction in hospital stays directly addresses one of healthcare's primary economic concerns: lowering the cost of care while improving patient outcomes. These findings reinforce previously published data and provide compelling evidence for both healthcare providers and payers to continue and potentially expand RECELL adoption.
VALENCIA, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today highlighted data presented by researchers at the British Burn Association (BBA) Annual Meeting demonstrating reduced length of hospital stay among burn patients treated with RECELL庐. The session, titled The Clinical Impact of Skin Cell Suspension Autograft from a National Registry Perspective, represents the largest real-world analysis of skin cell suspension autograft (commercially known as RECELL) to date.
The patented RECELL technology uses a small sample of a patient鈥檚 own skin to produce Spray-On Skin鈩� Cells, an autologous cell suspension that supports wound healing throughout the wound bed. Compared to traditional skin grafting, RECELL requires significantly less donor skin and offers a range of clinical benefits, including less pain at the donor site, faster healing, improved outcomes, and fewer procedures. These advantages contribute to shorter hospital stays and associated cost savings.
鈥淩educing hospital length of stay has a direct impact on the cost of care, especially in complex cases like severe burns,鈥� said Jim Corbett, Chief Executive Officer of AVITA Medical. 鈥淭his analysis further supports previously published data, reaffirming RECELL鈥檚 proven clinical and economic value by reducing hospital stays and accelerating patient recovery.鈥�
The retrospective study, presented by Jeffrey E. Carter, MD, FACS, FABA, of Louisiana State University Health and Sciences Center and University Medical Center in New Orleans, analyzed registry data from over 6,300 patients treated with RECELL between 2019 and 2024. Key findings from patients with burns covering less than
- Significant reduction for length of stay for patients treated with RECELL Spray-On Skin Cells alone by 6.2 days or
35.7% compared to those with split-thickness autografts - Cost savings of approximately
$300 million over the 5-year study period, driven by reduced length of stay
鈥淔rom a national registry perspective, we are seeing significant hospital savings and a clearer understanding of how newer technologies like RECELL impact clinical decisions, length of stay, and patient outcomes,鈥� said Dr. Carter.
RECELL is used in more than 130 burn centers across the United States.
About AVITA Medical, Inc.
AVITA Medical庐 is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL System庐, approved by the FDA for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient鈥檚 own skin to create Spray-On Skin鈩� Cells, offering an innovative solution for improved clinical outcomes at the point of care. In the U.S., AVITA Medical also holds the exclusive rights to manufacture, market, sell, and distribute PermeaDerm庐, a biosynthetic wound matrix, and the exclusive rights to market, sell, and distribute Cohealyx鈩�, an AVITA Medical-branded collagen-based dermal matrix.
In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns and full-thickness skin defects. The RECELL System, excluding RECELL GO庐, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.
To learn more, visit .
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements generally may be identified by the use of words such as 鈥渁nticipate,鈥� 鈥渆xpect,鈥� 鈥渋ntend,鈥� 鈥渃ould,鈥� 鈥渨ould,鈥� 鈥渕ay,鈥� 鈥渨ill,鈥� 鈥渂elieve,鈥� 鈥渃ontinue,鈥� 鈥渆stimate,鈥� 鈥渓ook forward,鈥� 鈥渇orecast,鈥� 鈥済oal,鈥� 鈥渢arget,鈥� 鈥減roject,鈥� 鈥渙utlook,鈥� 鈥済uidance,鈥� 鈥渇uture,鈥� and similar words or expressions, and the use of future dates. Forward-looking statements include, but are not limited to, statements relating to the timing and realization of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval or adoption of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and risks of other business effects, including the effects of industry, as well as other economic or political conditions outside of the Company鈥檚 control. These statements are made as of the date of this release, and the Company undertakes no obligation to publicly update or revise any of these statements, except as required by law. For additional information and other important factors that may cause actual results to differ materially from forward-looking statements, please see the 鈥淩isk Factors鈥� section of the Company鈥檚 latest Annual Report on Form 10-K and other publicly available filings for a discussion of these and other risks and uncertainties.
Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
Investor & Media Contact: Jessica Ekeberg [email protected] [email protected]
FAQ
What are the key findings of AVITA Medical's RECELL study for burn patients?
How many burn centers use RCEL's RECELL technology in the United States?
What are the main advantages of AVITA Medical's RECELL system over traditional skin grafting?
How many patients were included in AVITA Medical's RECELL real-world analysis?
How does RCEL's RECELL technology work?
